[Epidemiology of larynx carcinoma in the Lodz region]. / Epidemiologia raka krtani w regionie lódzkim.

The authors present epidemiology of the cancer in region of Lódz. The region of Lódz contains five provinces. In 1991 in this region were 532 males and 65 females with the cancer of larynx. The authors present coefficient: morbidity, mortality and disease in region of Lódz and in Poland in 1991.

[Diagnostic and therapeutic difficulties in tumors of neck and pharynx encountered in clinical cases]. / Trudnosci diagnostyczne i terapeutyczne w guzach szyi i gardla w oparciu o wlasny przypadek kliniczny.

The authors show case of lateral cervical cyst and carcinoma of the tonsil in woman 50 years, paying attention to large diagnostic and therapeutic difficulties. After operation of the lateral cervical cyst on the left side, metastasis of tumor followed, which was operated (after negative result of the thin-needle biopsy method) and histopathological examination of the tumor didn't prove atypical cells. In a few month after operation there followed tumorous infiltration in region angle of mandibula and in tonsillar region on the side and performed the thin-needle biopsy method showed planoepithelial carcinoma of the tonsil with transitional cells, which infiltrated the lingua, fundus of the oris and lymphonodes of the neck. Next the patient was sent to further treatment in the Oncological Hospital in Lodz. In connexion with advanced of the carcinoma, the using treatment (radiotherapy Co--60 and chemotherapy) was only the palliative treatment and prolongated life of the patient about 3 years.

[Thymoma and thymoma-like tumors of the anterior mediastinum--therapeutic problems in observed patients]. / Grasiczaki i guzy przedniego sródpiersia--problemy lecznicze u obserwowanych chorych.

In the last years, 11 patients with tumors of anterior mediastinum were treated at the Oncologic Centre in Lódz. Lymphocytic-epithelial thymoma was diagnosed in 6 patients whereas thymoma was suspected in 5 patients. Therapy was a problem mainly in these 5 patients, especially if lymphoma was considered in the differential diagnosis. The authors suggest that therapy should start with cytostatic agents in all patients with mediastinal tumors and morphology which not justifies thymoma diagnosis. Radiotherapy may follow in these cases in which 1-2 chemotherapy cycles failed.

51Cr-bleomycin in the diagnosis of tumours of the chest.

51Cr-bleomycin was used for the scintigraphic diagnosis of primary and secondary tumours of the thorax. The study was based on observations in 104 patients. The scintigraphy was performed using a gamma camera coupled to an on-line computer. Active lesions were scored using a semiquantitative scale of scores 0 to 5. Images were subdivided into 222 regions considered. In 72 of these, the presence of disease was diagnosed (64 malignant, 8 non-malignant) and 150 regions were classified as free from disease. At the decision threshold of score 2, over-all sensitivity and specificity of the scintigraphic detection of malignant tumours amounted to 97 and 79%, respectively. Inflammatory changes displayed some detectable accumulation of 51Cr-bleomycin but scores attributed to these lesions did not exceed the value of 2.

51Cr-bleomycin, a new oncophilic radiopharmaceutical. II. Scintigraphic diagnosis of malignant neoplasms.

51Cr-bleomycin was used for the scintigraphic detection of tumours and the assessment of the spread of the disease in 20 patients with various malignancies: 7 with Hodgkin's lymphoma, 5 with other malignant lymphomas, 4 cases of cervix carcinoma and 4 other tumours. The scintigraphy was performed using a Toshiba GC 401 gamma camera coupled to an MDSI computer Trinary. Active foci were scored using a semiquantitative scale of 0 to 5. Results of these studies were compared with those of tests similarly carried out with 57Co-bleomycin (in 9 of the cases) and 67Ga-citrate (11 cases); they demonstrated that the properties of 51Cr-bleomycin for scintigraphic detection of neoplastic foci are similar to those of 57Co-bleomycin.